Zelira Therapeutics (Zelira Therapeutics) FCF Margin % : -3,132.43% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Zelira Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Zelira Therapeutics's Free Cash Flow for the six months ended in Dec. 2023 was $-1.16 Mil. Zelira Therapeutics's Revenue for the six months ended in Dec. 2023 was $0.04 Mil. Therefore, Zelira Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -3,132.43%.

As of today, Zelira Therapeutics's current FCF Yield % is -98.70%.

The historical rank and industry rank for Zelira Therapeutics's FCF Margin % or its related term are showing as below:

ZLDAF' s FCF Margin % Range Over the Past 10 Years
Min: -2408.31 Med: -1990.07 Max: -611.75
Current: -1927.81

During the past 13 years, the highest FCF Margin % of Zelira Therapeutics was -611.75%. The lowest was -2408.31%. And the median was -1990.07%.

ZLDAF's FCF Margin % is ranked worse than
81.44% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs ZLDAF: -1927.81

Zelira Therapeutics FCF Margin % Historical Data

The historical data trend for Zelira Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelira Therapeutics FCF Margin % Chart

Zelira Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

-1,990.33

-611.73

-2,408.42

Zelira Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-634.93	-591.07	-4,678.85	-1,630.67	-3,132.43

Competitive Comparison of Zelira Therapeutics's FCF Margin %

For the Biotechnology subindustry, Zelira Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's FCF Margin % falls into.

Zelira Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Zelira Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-4.865	/	0.202
	=	-2,408.42 %

Zelira Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.159	/	0.037
	=	-3,132.43 %

Zelira Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Zelira Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zelira Therapeutics (Zelira Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (OTCPK:ZLDAF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

G1G:Germany ZLD:Australia

Address

101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000

Website

https://www.zeliratx.com

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.